In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma

Journal of Gene Medicine

Volumn 11, Issue 1, 2009, Pages 38-45

  Díez, Sonsoles ^a   Navarro, Gemma ^a   de ILarduya, Conchita Tros ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Asialofetuin; Asialoglycoprotein receptor; Gene delivery; Hepatocellular carcinoma; Interleukin 12; PLGA

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ASIALOFETUIN; ASIALOGLYCOPROTEIN RECEPTOR; CATION; GAMMA INTERFERON; INTERLEUKIN 12; LUCIFERASE; NANOPARTICLE; POLYGLACTIN; SOLVENT; 1,2 DIOLEOYLOXY 3 (TRIMETHYLAMMONIUM)PROPANE; 1,2-DIOLEOYLOXY-3-(TRIMETHYLAMMONIUM)PROPANE; ALPHA FETOPROTEIN; ASIALOGLYCOPROTEIN; LACTIC ACID; MONOUNSATURATED FATTY ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; EVAPORATION; FEMALE; GENE EXPRESSION; IN VIVO GENE TRANSFER; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CELL CARCINOMA; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SOLVENT EVAPORATION; TUMOR REGRESSION; TUMOR VOLUME; ZETA POTENTIAL; ANIMAL; CHEMISTRY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; LIVER TUMOR; METHODOLOGY; TRANSGENE; TUMOR CELL CULTURE;

ANIMALIA; MUS;

ALPHA-FETOPROTEINS; ANIMALS; ASIALOGLYCOPROTEINS; CARCINOMA, HEPATOCELLULAR; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INTERLEUKIN-12; LACTIC ACID; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; QUATERNARY AMMONIUM COMPOUNDS; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 59449091692     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1273     Document Type: Article

References (40)

1. Verma IM, Somia N. Gene therapy: promises, problems and prospects. Nature 1997; 389: 239-242.
2. Gerolami R, Uch R, Brechot C, Manizii P, Bagnis C. Gene therapy of hepatocarcinoma: a long way from the concept to the therapeutical impact. Cancer Gene Ther 2003; 10: 649-660.
3. Bowles NE, Eisensmith RC, Mohuiddin R, Pyron M, Woo SL. A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum Gene Ther 1996; 7: 1735-1742.
4. Kitten O, Cosset FL, Ferry N. Highly efficient retrovirus-mediated gene transfer into rat hepatocytes in vivo. Hum Gene Ther 1997; 8: 1491-1494.
5. Tsuchiyama T, Kaneko S, Nakamoto Y, et al. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther 2003; 10: 260-269.
6. Gerolami R, et al. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol 2004; 40: 291-297.
7. Ponnazhagan S, et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 1997; 190: 203-210.
8. Nakai H, et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998; 91: 4600-4607.
9. Cotten M, Wagner E, Zatloukal K, Phillips S, Curiel DT, Birnstiel ML. High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 1992; 89: 6094-6098.
10. Wagner E, et al. Coupling of adenovirus to transferrinpolylysine/ DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992; 89: 6099-6103.
11. Wu J, Zern MA. Modification of liposomes for liver targeting. J Hepatol 1996; 24: 757-763.
12. Tomita N, et al. In vivo gene transfer of insulin gene into neonatal rats by the HVJ-liposome method resulted in sustained transgene expression. Gene Ther 1996; 3: 477-482.
13. Cheng L, Ziegelhoffer PR, Yang NS. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc Natl Acad Sci USA 1993; 90: 4455-4459.
14. 2+ flux. Biochem Biophys Res Commun 1997; 234: 695-700.
15. Suzuki T, Shin BC, Fujikura K, Matsuzaki T, Takata K. Direct gene transfer into rat liver cells by in vivo electroporation. FEBS Lett 1998; 425: 436-440.
16. Hara T, Tan Y, Huang L. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel non-viral vector. Proc Natl Acad Sci USA 1997; 94: 14547-14552.
17. Malone RW, et al. Dexamethasone enhancement of gene expression after direct hepatic DNA injection. J Biol Chem 1994; 269: 29903-29907.
18. Wang D, Robinson DR, Kwon GS, Samuel J. Encapsulation of plasmid DNA in biodegradable poly (D,L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release 1999; 57: 9-18.
19. Cohen H, et al. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000; 7: 1896-1905.
20. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002; 16: 1217-1226.
21. Trere D, Fiume L, De Giorgi LB, Di Stefano G, Migaldi M, Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer 1999; 81: 404-408.
22. Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 1998; 27: 772-778.
23. Wang SL, Yu FB, Jiang TY, Sun CS, Wang T, Zhang JH. Design and synthesis of novel galactosylated polymers for liposomes as gene drug carriers targeting the hepatic asialoglycoprotein receptor. J Drug Target 2008; 16: 233-242.
24. Martinez-Fong D, Mullersman JE, Purchio AF, Armendariz-Borunda J, Martinez-Hernandez A. Non-enzymatic glycosylation of poly L-lysine: a new tool for targeted gene delivery. Hepatology 1994; 20: 1602-1608.
25. Peng DJ, et al. Inhibition of hepatocarcinoma by systemic delivery of apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther 2007; 14: 66-73.
26. Díez S, Miguéliz I, Tros de Ilarduya C. Targeted cationic poly (D, L-lactic-co-glycolic acid) nanoparticles for gene delivery. Cellular γ Molecular Biology Letters 2008; in press.
27. Arangoa MA, Düzgüneş N, Tros de Ilarduya C. Increased receptor-mediated gene delivery to the liver by protamineenhanced- asialofetuin-lipoplexes. Gene Ther 2003; 10: 5-14.
28. Kawakami S, Higuchi Y, Hashida M. Non-viral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci 2008; 97: 726-745.
29. Zanta MA, Boussif O, Adib A, Behr JP. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug Chem 1997; 8: 839-844.
30. Dasi F, Benet M, Crespo J, Crespo A, Alino SF. Asialofetuin liposome-mediated human alpha1-antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001; 79: 205-212.
31. Watanabe Y, Liu X, Shibuya I, Akaike T. Functional evaluation of poly (N-p-vinylbenzyl-O-beta-D-galactopyranosyl- [1-4]-Dgluconamide) (PVLA) as a liver specific carrier. J Biomater Sci Polym Ed 2000; 11: 833-848.
32. Niidome T, et al. Gene transfer into hepatoma cells mediated by galactose-modified alpha-helical peptides. Biomaterials 2000; 21: 1811-1819.
33. Labhasetwar V, Bonadio J, Goldstein AS, Levy RJ. Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model. Colloids Surf B Biointerfaces 1999; 16: 281-290.
34. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 1999; 88: 126-130.
35. Díez S, Tros de Ilarduya C. Versatility of biodegradable poly (D, L-lactic-co-glycolic acid)microspheres for plasmid DNA delivery. Eur J Pharm Biopharm 2006; 63: 188-197.
36. Shi F, et al. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 2002; 1: 949-957.
37. Iwasaki Y, et al. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther 2007; 14: 74-81.
38. Egilmez NK, Cuenca R, Yokota SJ, Sorgi F, Bankert RB. In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery. Gene Ther 1996; 3: 607-614.
39. Goto T, et al. Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo. Mol Ther 2004; 10: 929-937.
40. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 1997; 57: 2681-2686.